Table 3.
Proportion of patients in SUSTAIN-3 who attained response or remission status according to MADRS and PHQ-9 scores (LOCF)
| MADRS | PHQ-9 | |||
|---|---|---|---|---|
| PR-ESK+AD | PR-AD+PBO | PR-ESK+AD | PR-AD+PBO | |
| IND phase endpoint, n/N (%) | ||||
| ≥50% improvement from baselinea | 23/32 (71.9) | 47/64 (73.4) | 15/32 (46.9) | 40/63 (63.5) |
| Total score ≤12 (MADRS) or <5 (PHQ-9) | 20/32 (62.5) | 39/64 (60.9) | 7/32 (21.9) | 34/64 (53.1) |
| OP/M phase week 24, n/N (%) | ||||
| ≥50% improvement from baselinea | 12/32 (37.5) | 43/62 (69.4) | 10/32 (31.3) | 35/61 (57.4) |
| Total score ≤12 (MADRS) or <5 (PHQ-9) | 13/32 (40.6) | 36/62 (58.1) | 9/32 (28.1) | 26/62 (41.9) |
| OP/M phase week 52, n/N (%) | ||||
| ≥50% improvement from baselinea | 13/32 (40.6) | 34/62 (54.8) | 10/32 (31.3) | 30/61 (49.2) |
| Total score ≤12 (MADRS) or <5 (PHQ-9) | 12/32 (37.5) | 26/62 (41.9) | 9/32 (28.1) | 21/62 (33.9) |
AD antidepressant, IND induction, LOCF last observation carried forward, MADRS Montgomery-Åsberg Depression Rating Scale, OP/M optimization/maintenance phase, PHQ-9 Patient Health Questionnaire 9-item, PR-AD+PBO previously relapsed on an oral AD plus placebo, PR-ESK+AD previously relapsed on esketamine nasal spray plus an oral AD
aBaseline was defined as before SUSTAIN-3